

Edgar Filing: NOVARTIS AG - Form 6-K

NOVARTIS AG  
Form 6-K  
June 26, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated June 26, 2002

Novartis AG  
(Name of Registrant)

Lichtstrasse 35  
4056 Basel  
Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file  
annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F  
-- --

Indicate by check mark whether the registrant by furnishing the information  
contained in this form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X  
-- --

Enclosures:

1. Invitation for Telephone Conference, First Half 2002 Sales & Results; and
2. Pre-Results Announcement, Quarterly Breakdown 2001.

NOVARTIS LOGO

Investor Relations

Novartis International AG  
CH-4002 Basel  
Switzerland  
Karen J Huebscher, PH.D.  
Tel +41 61 324 8433  
Nafida Bendali  
Tel +41 61 324 3514  
Sabine Moravi, MBA  
Tel + 41 61 324 8989  
Fax + 41 61 324 8844

Edgar Filing: NOVARTIS AG - Form 6-K

Silke Zentner  
Tel + 41 61 324 8612  
Francisco Bouzas  
Tel + 41 61 324 2462  
Fax + 41 61 324 8844  
Internet Address:  
<http://www.novartis.com>

- INVITATION FOR TELEPHONE CONFERENCE -

First Half 2002 Sales & Results

Dear Investor

We are pleased to invite you to our First Half Sales & Results 2002 conference call. Please below the following dial-in numbers:

Date: Monday, July 22, 2002

Time: Advisable: dial-in 10 minutes before  
06.00 p.m. Switzerland  
05.00 p.m. UK  
12.00 p.m. New York

Phone numbers: +41 91 610 4111 or Free-phone +800 2467 8700 Europe and ROW  
+1 800 860 2442 US

You may access the conference call as a live audio webcast on the Internet:  
<http://www.novartis.com/investors> (under Upcoming Event). This information will be available for tests and for the submission of questions in advance from July 15, 2002 on.

Additional information will be available on Monday, July 22, on the Internet  
[http://www.novartis.com/investors/sales\\_results\\_releases.shtml](http://www.novartis.com/investors/sales_results_releases.shtml)

Playback for 48 hours

Date: Monday, July 22, 2002

Time: 07.00 p.m. Switzerland  
06.00 p.m. UK  
01.00 p.m. New York

Phone numbers: +41 91 612 43 30 Europe and ROW  
+1 877 344 7529 US

Code: 335 (followed by the # sign)

NOVARTIS LOGO

Pre-Results Announcement

Quarterly Breakdown 2001

Investor Relations, June 2002

## Edgar Filing: NOVARTIS AG - Form 6-K

Comments

---

On the following slides you will find for 2001

- o Sector sales and operating income figures updated for the split of Consumer Health into OTC, Medical Nutrition and Infant & Baby
- o Sector sales figures showing a regional breakdown into US and RoW
- o Breakdown of quarterly operating margins

NOVARTIS LOGO

Quarterly Breakdown of Sales by Sector 2001

---

Group	First Quarter		Q1 Total	Second Quarter		Half Year Total
	US	RoW		US	RoW	
	CHF m	CHF m	CHF m	CHF m	CHF m	CHF
Group	2,876	4,348	7,224	3,341	4,702	15,266
Pharmaceuticals	1,793	2,745	4,538	2,174	2,977	9,680
Generics	156	372	528	176	417	1,121
OTC	175	426	601	181	432	1,213
Animal Health	75	165	240	74	176	495
Medical Nutrition & HFF	97	276	373	111	293	777
Infant & Baby	401	120	521	427	147	1,095
CIBA Vision	179	244	423	198	260	888

NOVARTIS LOGO

Quarterly Breakdown of Sales by Sector 2001

---

Group	Third Quarter		Q3 Total	Fourth Quarter		Full Year Total
	US	RoW		US	RoW	
	CHF m	CHF m	CHF m	CHF m	CHF m	CHF
Group	3,665	4,452	8,117	3,604	4,655	31,640
Pharmaceuticals	2,395	2,812	5,207	2,275	3,010	20,180

Edgar Filing: NOVARTIS AG - Form 6-K

Generics	228	408	636	229	447	2,43
OTC	230	422	652	246	426	2,53
Animal Health	78	147	225	103	144	96
Medical Nutrition & HFF	109	256	365	129	244	1,51
Infant & Baby	412	135	547	453	132	2,22
CIBA Vision	214	271	485	169	252	1,78

NOVARTIS LOGO

Sales Adjustments<sup>1</sup> For 2001

	Q1 CHF m	Q2 CHF m	Half Year	Q3 CHF m	Q4 CHF m	Full Year CHF m
	-----	-----	-----	-----	-----	-----
Group	-96	-101	-197	-103	-95	-39
OTC	-30	-29	-59	-29	-41	-12
Infant & Baby	-55	-55	-110	-66	-40	-21
Medical Nutrition & HFF	-11	-17	-28	-8	-14	-5

<sup>1</sup> adjustments for changes in accounting policy on sales incentives and discounts to retailers

NOVARTIS LOGO

Quarterly Breakdown of Operating Income by Sector 2001

	Q1 CHF m	Q2 CHF m	Half Year CHF m	Q3 CHF m	Q4 CHF m	Full Year CHF m
	-----	-----	-----	-----	-----	-----
Group	1,545	1,935	3,480	1,873	1,924	7,277
Pharmaceuticals	1,244	1,451	2,695	1,436	1,546	5,677
Generics	65	76	141	68	72	281
OTC	58	92	150	128	174	452
Animal Health	44	22	66	30	42	138

Edgar Filing: NOVARTIS AG - Form 6-K

Medical Nutrition & HFF	18	24	42	17	21	80
Infant & Baby	90	103	193	94	101	388
CIBA Vision	6	81	87	69	18	174
Corporate income, net	20	86	106	31	-50	87

NOVARTIS LOGO

Quarterly Breakdown of Operating Margins by Sector 2001

	Q1 in % ----	Q2 in % ----	Half Year in % -----	Q3 in % ----	Q4 in % ----	Full Year in % -----
Group	21.4	24.1	22.8	23.1	23.3	23.0
Pharmaceuticals	27.4	28.2	27.8	27.6	29.3	28.1
Generics	12.3	12.8	12.6	10.7	10.7	11.5
OTC	9.7	15.0	12.4	19.6	25.9	17.8
Animal Health	18.3	8.8	13.5	13.3	17.0	14.3
Medical Nutrition & HFF	4.8	5.9	5.4	4.7	5.6	5.3
Infant & Baby	17.3	17.9	17.6	17.2	17.3	17.4
CIBA Vision	1.4	17.7	9.9	14.2	4.3	9.7

NOVARTIS LOGO

2001 Quarterly Consolidated Income Statement

Quarterly Breakdown of Operating Margins by Sector 2001

	Q1 CHF millions -----	Q2 CHF millions -----	1H2001 CHF millions -----	Q3 CHF millions -----	Q4 CHF millions -----
Total sales	7,224	8,043	15,267	8,117	8,117
Cost of goods sold	-1,874	-1,930	-3,804	-2,000	-2,000
Gross profit	5,350	6,113	11,463	6,117	6,117
Marketing & Distribution	-2,499	-2,766	-5,265	-2,689	-2,689
Research & Development	-929	-1,081	-2,010	-1,057	-1,057

## Edgar Filing: NOVARTIS AG - Form 6-K

General & Administration	-377	-331	-708	-498
Operating income	1,545	1,935	3,480	1,873
Income from associated companies	31	46	77	23
Financial income, net	217	735	952	197
Income before taxes and minority interests	1,793	2,716	4,509	2,093
Taxes	-305	-463	-768	-399
Minority interests	-3	-9	-12	-11
Net income	1,485	2,244	3,729	1,683

NOVARTIS LOGO

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novartis AG

Date: June 26, 2002

By: /s/ MALCOLM B. CHEETHAM

-----  
Name: Malcolm B. Cheetham  
Title: Head Group Financer  
Group Fin. Reporting and Accounting